Cetera Advisor Networks LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

Cetera Advisor Networks LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 2.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 926,985 shares of the biopharmaceutical company’s stock after acquiring an additional 21,943 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Pfizer were worth $34,002,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 3.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 86,378,754 shares of the biopharmaceutical company’s stock valued at $3,152,574,000 after acquiring an additional 2,477,573 shares during the period. Oxler Private Wealth LLC raised its position in Pfizer by 1.1% in the second quarter. Oxler Private Wealth LLC now owns 60,544 shares of the biopharmaceutical company’s stock valued at $2,221,000 after purchasing an additional 633 shares during the period. Karpas Strategies LLC lifted its stake in shares of Pfizer by 0.5% during the second quarter. Karpas Strategies LLC now owns 141,296 shares of the biopharmaceutical company’s stock worth $5,183,000 after purchasing an additional 691 shares in the last quarter. Beverly Hills Private Wealth LLC boosted its position in shares of Pfizer by 71.8% in the second quarter. Beverly Hills Private Wealth LLC now owns 150,332 shares of the biopharmaceutical company’s stock worth $5,265,000 after buying an additional 62,835 shares during the period. Finally, AlphaCore Capital LLC grew its stake in shares of Pfizer by 128.8% in the second quarter. AlphaCore Capital LLC now owns 60,106 shares of the biopharmaceutical company’s stock valued at $2,205,000 after buying an additional 33,831 shares in the last quarter. 68.05% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE stock opened at $30.19 on Thursday. The firm has a market cap of $170.47 billion, a P/E ratio of 16.50, a P/E/G ratio of 1.86 and a beta of 0.63. The stock’s 50 day simple moving average is $32.15 and its 200 day simple moving average is $35.38. The company has a current ratio of 2.38, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $28.93 and a 12-month high of $54.93.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.15. Pfizer had a net margin of 15.30% and a return on equity of 16.72%. The company had revenue of $13.23 billion for the quarter, compared to analysts’ expectations of $13.77 billion. As a group, equities research analysts predict that Pfizer Inc. will post 1.56 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Friday, November 10th will be paid a $0.41 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.64 dividend on an annualized basis and a yield of 5.43%. Pfizer’s payout ratio is currently 89.62%.

Wall Street Analyst Weigh In

PFE has been the topic of several recent research reports. Jefferies Financial Group raised Pfizer from a “hold” rating to a “buy” rating and boosted their price target for the stock from $38.00 to $39.00 in a research report on Monday, October 16th. Wells Fargo & Company reduced their target price on shares of Pfizer from $39.00 to $35.00 and set an “equal weight” rating on the stock in a research report on Monday, October 16th. Morgan Stanley lowered their price target on shares of Pfizer from $39.00 to $37.00 and set an “equal weight” rating for the company in a report on Wednesday, November 1st. JPMorgan Chase & Co. cut their price objective on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Finally, Truist Financial decreased their price objective on shares of Pfizer from $62.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, October 17th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $42.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.